At the just-concluded 2023 American Society of Nephrology (ASN) Annual Meeting Kidney Week, the Nephrology research team of Guangdong Provincial People's Hospital had 6 research results successfully selected for presentation, showcasing the department's recent basic and clinical research achievements in the field of chronic kidney disease. These results have garnered significant attention from domestic and international scholars.

Among them, a Phase 3 clinical study of Enarodustat led by Professor Yu Xueqing from Guangdong Provincial People's Hospital, involving 48 centers nationwide, made its global debut at the conference. The research results were first reported at the 2023 ASN Annual Meeting and were included in the Late-Breaking Science (LBS) program. 

It was a randomized, double-blind, placebo-controlled, open-label extension, multi-center clinical research. It comprised a 4-week screening period, an 8-week double-blind period (DBP), a 16-week open-label period (OLP), and a 2-week safety follow-up period. The Enarodustat phase 3 clinical data from China, reported at the 2023 ASN Meeting, demonstrated that the new generation HIF-PHI generic drug effectively improves iron absorption and utilization, maintains iron homeostasis, and boosts Hb levels efficiently while promoting endogenous EPO at physiological concentrations. It exhibited good performance in terms of efficacy and safety. By meeting clinical needs such as reducing the frequency of dose adjustments and ensuring drug safety, Enarodustat may help achieve long-term management of renal anemia and become the preferred treatment for renal anemia.

In addition, research findings from Professor Liang Xinling, Professor Wang Wenjian, and Professor Bai Xiaoyan of the Department of Nephrology were also presented at the poster sessions.

Department of Nephrology

Updated: November 30, 2023